Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention


  Free Subscription


1 Am J Med
1 Ann Intern Med
1 J Clin Endocrinol Metab
1 J Natl Cancer Inst
3 Osteoporos Int

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Am J Med

  1. ALSOOF D, Anderson G, McDonald CL, Basques B, et al
    Diagnosis and Management of Vertebral Compression Fracture.
    Am J Med. 2022;135:815-821.
    PubMed         Abstract available

    Ann Intern Med

  2. CENTOR RM, Hayes KN
    Web Exclusive. Annals On Call - Time for a Bisphosphonate Holiday?
    Ann Intern Med. 2022;175:OC1.

    J Clin Endocrinol Metab

  3. OHEIM R, Tsourdi E, Seefried L, Beller G, et al
    Genetic Diagnostics in Routine Osteological Assessment of Adult Low Bone Mass Disorders.
    J Clin Endocrinol Metab. 2022;107:e3048-e3057.
    PubMed         Abstract available

    J Natl Cancer Inst

  4. Correction to: Nitrogen-based Bisphosphonate Use and Ovarian Cancer Risk in Women Aged 50 Years and Older.
    J Natl Cancer Inst. 2022 Jun 17. pii: 6609827. doi: 10.1093.

    Osteoporos Int

  5. ABDALBARY M, Sobh M, Elnagar S, Elhadedy MA, et al
    Management of osteoporosis in patients with chronic kidney disease.
    Osteoporos Int. 2022 Jun 24. pii: 10.1007/s00198-022-06462.
    PubMed         Abstract available

  6. BONLOKKE SE, Rand MS, Haddock B, Arup S, et al
    Baseline bone turnover marker levels can predict change in bone mineral density during antiresorptive treatment in osteoporotic patients: the Copenhagen bone turnover marker study.
    Osteoporos Int. 2022 Jun 21. pii: 10.1007/s00198-022-06457.
    PubMed         Abstract available

  7. DUONG LT, Clark S, Pickarski M, Giezek H, et al
    Effects of odanacatib on bone-turnover markers in osteoporotic postmenopausal women: a post hoc analysis of the LOFT study.
    Osteoporos Int. 2022 Jun 17. pii: 10.1007/s00198-022-06406.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Osteoporosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.